Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Summary

This is a single-arm, open-label study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).

Timeline

Start

2023-12-22

Primary completion

2024-06-29

Completion

2024-08-23

Outcome

Met primary endpoint

release “在一项单臂概念验证性Ⅱ期临床研究中，芮弗西拜单抗治疗成人HoFH患者的LDL-C降幅达59.1%” hengrui.com ↗

Publications

• Peng D, Wang L, Pi L, Xu Y, Chen J, Wu Y, Wang N, Chen X, Qi S, Feng S, Cheng G, Lv C, Zhu M, Zhu Y. Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. JAMA Cardiol. 2026 Feb 1;11(2):193-198. doi: 10.1001/jamacardio.2025.4878.

Drugs

Indications